Skip to main content
Erschienen in: Pathology & Oncology Research 3/2016

20.11.2015 | Original Article

Prognostic Factors for Breast Cancer: an Immunomorphological Update

verfasst von: Luca Roncati, Giuseppe Barbolini, Federico Piacentini, Francesco Piscioli, Teresa Pusiol, Antonio Maiorana

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The prognostic variability recorded within homogeneous groups of patients for anatomo-clinical disease stages has led to a more detailed biological characterization of breast cancer. Recently, the attention of the scientific community has focused on the role of tumor-infiltrating lymphocytes (TILs). Therefore, the need of an in-depth immunomorphological characterization of TILs has been emerged. The presence of TILs has been retrospectively investigated in 113 female cases of ductal carcinoma. An immunohistochemical investigation with CD3, CD4, CD8, CD20, CD56, granulysin, perforin-1, granzyme-B and TIA-1 was performed according to the standard procedures on all 17 cases with TILs evidence. TILs consisted of T and B lymphocytes: the prevalent population showed a T immunoprofile with a CD8-immunopositive killer subpopulation (Tk), close-linked to carcinomatous cells, and a CD4-immunopositive helper subpopulation (Th), inside the tumor. A time sequence (firstly T, then B) has been disclosed. Granulysin, perforin, granzyme-B and TIA-1 were expressed by Tk cells. The activated Tk cells secrete these mediators as a result of the binding to the tumor target cell, causing its lytic planned death. The cytotoxicity supported by Tk cells appears an important favorable prognostic factor. Therefore, a graduation system for TILs in breast cancer has been here proposed (absent, non-brisk, brisk).
Literatur
1.
Zurück zum Zitat World Health Organization. International Agency for Research on Cancer (2014) Breast cancer. Chapter 5.2. In: World Cancer Report 362–373 World Health Organization. International Agency for Research on Cancer (2014) Breast cancer. Chapter 5.2. In: World Cancer Report 362–373
2.
Zurück zum Zitat Denoix PF (1946) Enquete permanent dans les centres antercancereux. Bull Inst Hyg 1:70 Denoix PF (1946) Enquete permanent dans les centres antercancereux. Bull Inst Hyg 1:70
3.
Zurück zum Zitat Rathore AS, Kumar S, Konwar R, Srivastava AN, Makker A, Goel MM (2013) Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer 50:239–244CrossRefPubMed Rathore AS, Kumar S, Konwar R, Srivastava AN, Makker A, Goel MM (2013) Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer 50:239–244CrossRefPubMed
4.
Zurück zum Zitat Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550CrossRefPubMed Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550CrossRefPubMed
5.
Zurück zum Zitat Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 25:611–618CrossRefPubMedPubMedCentral Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 25:611–618CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng WY, Ou Yang TH, et al. (2014) JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunol Res 2:301–306CrossRefPubMedPubMedCentral Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng WY, Ou Yang TH, et al. (2014) JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunol Res 2:301–306CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713CrossRefPubMedPubMedCentral Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, et al. (2014) Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One 9:e95475CrossRefPubMedPubMedCentral Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, et al. (2014) Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One 9:e95475CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Melichar B, Študentova H, Kalábová H, Vitásková D, Čermáková P, Hornychová H, et al. (2014) Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res 34:1115–1125PubMed Melichar B, Študentova H, Kalábová H, Vitásková D, Čermáková P, Hornychová H, et al. (2014) Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res 34:1115–1125PubMed
11.
Zurück zum Zitat Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109:2796–2801CrossRefPubMedPubMedCentral Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109:2796–2801CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hussein MR, Hassan HI (2006) Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 59:972–977CrossRefPubMedPubMedCentral Hussein MR, Hassan HI (2006) Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 59:972–977CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Tian Q, Taupin J, Elledge S, Robertson M, Anderson P (1995) Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 182:865–874CrossRefPubMed Tian Q, Taupin J, Elledge S, Robertson M, Anderson P (1995) Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 182:865–874CrossRefPubMed
14.
Zurück zum Zitat Zhou J, Xu XZ, Hu YR, Hu AR, Zhu CL, Gao GS (2014) Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4+ T cells through the JAK2/STAT4/perforin pathway. Asian Pac J Cancer Prev 15:2439–2445CrossRefPubMed Zhou J, Xu XZ, Hu YR, Hu AR, Zhu CL, Gao GS (2014) Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4+ T cells through the JAK2/STAT4/perforin pathway. Asian Pac J Cancer Prev 15:2439–2445CrossRefPubMed
15.
Zurück zum Zitat Roncati L, Barbolini G, Rivasi F (2010) Vascular endothelial growth factor/receptor systems expressed by basophils in vaginal angiomyofibroblastoma. Pathologica 102:351 Roncati L, Barbolini G, Rivasi F (2010) Vascular endothelial growth factor/receptor systems expressed by basophils in vaginal angiomyofibroblastoma. Pathologica 102:351
16.
Zurück zum Zitat Busam KJ, Antonescu CR, Marghoob AA, Nehal KS, Sachs DL, Shia J, et al. (2001) Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. Am J Clin Pathol 115:856–860CrossRefPubMed Busam KJ, Antonescu CR, Marghoob AA, Nehal KS, Sachs DL, Shia J, et al. (2001) Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. Am J Clin Pathol 115:856–860CrossRefPubMed
17.
Zurück zum Zitat Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S (2005) Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 446:10–14CrossRefPubMed Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S (2005) Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 446:10–14CrossRefPubMed
18.
Zurück zum Zitat Manenti A, Roncati L, Sighinolfi P, Barbolini G (2014) Absence of immune response as a sign of tissue tolerance in small-cell lung cancer. Gene Cell Tissue 1:e20330CrossRef Manenti A, Roncati L, Sighinolfi P, Barbolini G (2014) Absence of immune response as a sign of tissue tolerance in small-cell lung cancer. Gene Cell Tissue 1:e20330CrossRef
Metadaten
Titel
Prognostic Factors for Breast Cancer: an Immunomorphological Update
verfasst von
Luca Roncati
Giuseppe Barbolini
Federico Piacentini
Francesco Piscioli
Teresa Pusiol
Antonio Maiorana
Publikationsdatum
20.11.2015
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2016
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-015-0024-7

Weitere Artikel der Ausgabe 3/2016

Pathology & Oncology Research 3/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.